substitution with a phenyl group slightly increased activ

Lenalidomide As a means of improving the immunomodulatory effects and beating the nonhematological negative events of thalidomide, analogs including Lenalidomide lenalidomide have now been developed. Like thalidomide, lenalidomide exerts pleiotropic effects, including immunomodulatory, antiangiogenic, and anti-neoplastic activities. In preclinical studies, lenalidomide has demonstrated more potent anti MM action than its parent compound and its toxicity profile is more favorable. After complete phase I and phase II trials in high level MM, followed by two pivotal phase III trials, lenalidomide was authorized by the US FDA and by the European Medicines Agency in June 200770 for use in combination with dexamethasone in treating MM in patients who have received one or more prior therapy. Gene expression Mechanism of action in MM The molecular mechanisms associated with disease progression in MM are determined by the interaction between MM cells and the bone marrow microenvironment. Fleetingly, the adhesion of MM cells to bone-marrow stromal cells causes the release of cytokines that mediate individual pathways of MM cell growth and survival, including antiapoptosis, proliferation, cell cycle progression, and migration. Stromal cell derived IL 6, tumefaction necrosis factor alpha and vascular endothelial growth factor, for instance, take part in the service of a few MM cell signaling pathways, including phosphatidylinositol 3 kinase /Akt, Janus kinase /signal transducer and activator of transcription 3, Raf/Mek/ mitogen activated protein kinase, and NF B, as well as their downstream targets. Lenalidomide ARN-509 continues to be proven to affect many of the interactions central to myeloma development by both direct and indirect systems. The immediate effects of lenalidomide include induction of apoptosis or cell cycle arrest of indirect effects and the tumor cell involving change of the tumor microenvironment and augmentation of the innate and acquired immune responses. Combined, these effects bring about effective tumor cell reduction and suppression. This duality of action may be essential in treating MM. The logical development of being an anti-cancer agent lenalidomide used the success of thalidomide, an effective inhibitor of TNF with antiangiogenesis activity and T-cell costimulatory activity. In contrast to its parent compound, lenalidomide can be a more powerful inhibitor of TNFsecretion by activated monocytes. As well as TNF, lenalidomide also inhibits transforming growth factor beta and the proinflammatory cytokines, IL 1, IL 6, and IL 12, while secretion of the anti-inflammatory cytokine IL 10 appears to be improved by lenalidomide.